Early KPC-Producing Klebsiella pneumoniae Bacteremia among Intensive Care Unit Patients Non-Colonized upon Admission by Papadimitriou-Olivgeris, Matthaios et al.
Polish Journal of Microbiology
2017,  Vol. 66,  No 2,  251–254
SHORT COMMUNICATION
* Corresponding author: M. Marangos, Division of Infectious Diseases, University of Patras, School of Medicine, Rion – Patras, 
Greece; e-mail: mmarangos@yahoo.com 
Carbapenemase-producing Klebsiella pneumoniae, 
and especially KPC-producing (KPC-Kp) constitutes 
an important worldwide issue since it is endemic in 
many countries and provokes serious infections asso-
ciated with increased mortality especially among 
patients hospitalized in Intensive Care Units (ICUs) 
(Falcone et al., 2016). Many patients develop primary 
bacteremia probably due to bacterial translocation, sug-
gesting that enteric colonization is an important first 
step for the induction of infection (Schechner et al., 
2013; Giannella et al., 2014; Giacobbe et al., 2015). 
It is reported that 16.5% (7.6–44.4%) of colonized 
patients develop a bloodstream infection (BSI), which 
renders the surveillance with rectal swabs imperative 
for every infection control program (Borer et al., 2012; 
Tischendorf et al., 2016).
The aim of the present study was to determine the 
risk factors for early KPC-Kp BSI (during the first nine 
days of ICU stay) among non-colonized patients upon 
admission in two Greek ICUs. 
This retrospective study was performed in the ICUs 
of the University General Hospital of Patras, Greece 
(13  beds) during a 28-month period (November 
2009-February 2012) and of the General Hospital of 
Patras “Agios Andreas” (6  beds) during a 16-month 
period (November 2009-February 2011). Epidemio-
logic data were collected from patients’ chart reviews. 
The study was carried out under the Hospital Surveil-
lance Programme for multi-drug resistant infections of 
hospitalized patients, and was approved by the Univer-
sity Hospital Ethics Committee (HEC No: 571). 
According to CDC definition, BSI was defined 
as presence of at least one positive blood culture for 
K. pneumoniae and clinical symptoms consistent with 
bacteremia. Rectal samples were obtained upon ICU 
admission and afterwards at days 4, 7 and once weekly 
until discharge. Only patients that had an ICU stay of 
at least seven days were included. Swabs were inocu-
lated on a selective chromogenic agar (CHROMagar™ 
KPC, Paris, France) and incubated at 37°C for 24 hours. 
Representative colonies were identified as K. pneumo-
niae by standard methods and Vitek 2 Advanced Expert 
System (bioMerieux, Marci l’Etoile, France).
Susceptibility to carbapenems (imipenem, mero-
penem, ertapenem), colistin and tigecycline was deter-
mined by Etest (bioMerieux) whereas, susceptibility to 
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A b s t r a c t
Among 140 patients colonized by KPC-producing Klebsiella pneumoniae (KPC-Kp) between fourth and seventh day of Intensive Care 
Unit stay, 24 developed bacteraemia immediately after colonization. Colistin-resistance of the colonizing isolate was the factor significantly 
associated with early KPC-Kp bacteraemia (P < 0.001; OR 6.6, 95% CI 2.4–18.4), a worrisome finding since infections by colistin-resistant 
isolates is associated with increased mortality due to limited remaining therapeutic options. 
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Demographics
Age (years)   57.6 ± 18.4 54.8 ± 17.8 0.500
Male gender   83 (71.6%) 16 (66.7%) 0.629
Chronic diseases (number)   0.9 ± 1.0  0.8 ± 1.0 0.929
Diabetes Mellitus  15 (12.9%)  1 (4.2%) 0.307
Chronic Obstructive Pulmonary Disease  16 (13.8%)  1 (4.2%) 0.306
Chronic Heart Failure  13 (11.2%)  1 (4.2%) 0.464
Chronic Renal Failure   4 (3.4%)  2 (8.3%) 0.273
Malignancy  11 (9.5%)  3 (12.5%) 0.708
Cortisone use   8 (6.9%)  1 (4.2%) 1.000
Obesity  30 (25.9%)  8 (33.3%) 0.458
Admission data
APACHE II Score upon admission   17.1 ± 7.0 16.0 ± 8.1 0.499
SAPS II Score upon admission   39.2 ± 13.4 34.8 ± 9.5 0.156
SOFA Score upon admission   8.1 ± 3.4  8.9 ± 3.4 0.296
Respiratory insufficiency   25 (21.6%)  6 (25.0%) 1.000
Prior emergency surgery  46 (39.7%) 10 (41.7%) 1.000
Prior abdominal surgery  32 (27.6%)  6 (25.0%) 1.000
Antibiotics administered
Carbapenems  101 (87.1%) 23 (95.8%) 0.307
Quinolones   19 (16.4%)  4 (16.7%) 1.000
3rd- and 4th-generation cephalosporins  16 (13.8%)  2 (8.3%) 0.738
Piperacillin/tazobactam   30 (25.9%) 10 (41.7%) 0.139
Colistin  29 (25.0%) 10 (41.7%) 0.132
Aminoglycosides   30 (25.9%) 10 (41.7%) 0.139
Glycopeptides   95 (81.9%) 21 (87.5%) 0.766
Metronidazole   17 (14.7%)  4 (16.7%) 0.759
Tigecycline    3 (2.6%)  0 (0.0%) 1.000
Linezolid   19 (16.4%)  3 (12.5%) 0.766
Mean antibiotic use per day    2.6 ± 1.0  2.6 ± 0.6 0.324
Hospitalization data
Mechanical ventilation 115 (99.1%) 24 (100%) 1.000
Tracheostomy  49 (42.2%) 16 (66.7%) 0.042
Number of cathetersα    1.1 ± 1.3  1.4 ± 1.4 0.208
Abdominal catheter and/or colostomy  27 (23.3%)  6 (25.0%) 0.798
Dialysis  12 (10.3%)  5 (20.8%) 0.172
Cortisone administration  58 (50.0%) 16 (66.7%) 0.179
Parenteral nutrition  49 (42.2%) 14 (54.2%) 0.367
Enteral nutrition  74 (63.8%) 16 (66.7%) 1.000
Resistance of colonizing isolate
Imipenem resistance  56 (48.3%) 18 (75.0%) 0.024
Gentamicin resistance  36 (31.0%) 14 (58.3%) 0.018
Colistin resistance  22 (19.0%) 14 (58.3%) < 0.001 < 0.001 6.6 (2.4–18.4)
Tigecycline resistance    18 (15.5%)  9 (37.5%) 0.021
Table I
Univariate and multivariate analyses of risk factors for KPC-producing K. pneumoniae (KPC-Kp) bloodstream infection (BSI)
immediately after early enteric colonization during Intensive Care Unit (ICU) hospitalization.
Data are number (%) of patients or mean ±standard deviation 
Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation I; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential 
Organ Failure Assessment; α All patients after ICU admission were intubated, mechanically ventilated and were continuously monitored with a central 
venous catheter, an arterial catheter and a urinary catheter. Number of catheters does not include the aforementioned catheters.
Characteristics
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other antimicrobials (amoxicillin/clavulanic acid, piper-
acillin, cefoxitin, ceftriaxone, aztreonam, ciprofloxacin, 
co-trimoxazole, amikacin, gentamicin) was determined 
by the disk diffusion method. Results were interpreted 
according to EUCAST guidelines (EUCAST, 2016). 
Presence of blaKPC gene in all K. pneumoniae strains was 
confirmed by PCR (Queenan and Bush, 2007)
Statistical analysis was performed with SPSS ver-
sion 22.0 (SPSS, Chicago, IL) software. Categorical vari-
ables were analyzed by using the Fisher exact test or chi2 
and continuous variables with Mann-Whitney U test, 
as appropriate. Backward stepwise multiple logistic 
regression analysis used all those variables from the 
univariate analysis with a P < 0.1. Odds ratios (ORs) 
and 95% confidence intervals (CIs) were calculated to 
evaluate the strength of any association. All statistic 
tests were 2-tailed and P < 0.05 was considered statisti-
cally significant.
From 349 patients that had an ICU stay of at least 
seven days in both ICUs, 304 were not colonized by 
KPC-Kp upon admission. Among them, 140 patients 
(46.1%) were colonized in day seven and they were 
included in the analysis. No patient was colonized 
in fourth day. In total 58 patients (16.6%) developed 
KPC-Kp BSI within an average of 19.3 days, from which 
24 (41.4%) within nine days of ICU stay (two days after 
colonization). Table I shows the univariate and multi-
variate analyses of factors that differed among patients 
that developed a KPC-Kp BSI until day nine of ICU stay 
and those that did not. Multivariate analysis revealed 
that colistin-resistance of the colonizing isolate was sig-
nificantly associated with early KPC-Kp BSI. 
A high percentage of patients admitted in the ICU 
(46.1%) were colonized during their first seven days of 
their stay, while 17.1% among them developed a BSI 
within two days from enteric colonization. In contrast, 
in previous studies (Schechner et al., 2013; Giannella 
et al., 2014), colonization preceded infection by 11 
(range 3–27) and 19 days (range 6–28), far later than 
in our study (8 days; range 1–25). 
The only independent factor associated with the 
occurrence of bacteremia was the resistance of colo-
nizing isolate to colistin, since among 36 colistin-
resistant KPC-Kp colonizing isolates, 14 (38.9%) 
resulted in immediate bacteremia, while no difference 
in colistin administration was observed among infec- 
ted and colonized patients (25.9% vs 41.7%; P 0.132). 
This finding suggests that not all KPC-Kp isolates 
share the same virulence capacity, consistent with 
results of previous studies (Diago-Navarro et al., 2014; 
Chiang et al., 2016). The capacity of colistin-resistant 
isolates to induce infection is a worrisome finding since 
BSI from such isolates is associated with increased mor-
tality due to limited remaining therapeutic options 
(Giacobbe et al., 2015, Falcone et al., 2016). As pre-
viously shown, colonization by colistin-resistant iso-
late was a prerequisite to an infection by such isolate 
(Giacobbe et al., 2015).
Chronic diseases, invasive procedures, severity of 
disease and antibiotic administration were commonly 
identified as risk factors for infections by carbapen-
emase-producing K. pneumoniae (Borer et al., 2012; 
Schechner et al., 2013; Giannella et al., 2014; Giacobbe 
et al., 2015, Falcone et al., 2016). In contrast to pre-
vious studies, none of aforementioned factors differed 
between colonized and infected patients in the present 
study, suggesting that induction of BSI by translocation 
may be mostly influenced by bacteria’s than patients’ 
characteristics.
The present study has limitations; it was conducted 
in two Greek ICUs with high colonization rates and 
results might not be generalized for other institutions. 
Another limitation is its retrospective nature and the 
small number of patients included.
To conclude, a high percentage of ICU patients 
developed bacteremia by KPC-Kp within two days 
from colonization, a finding more common for colistin-
resistant isolates.
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